Contents

for authors

Cart

quick search

Cart

Your cart is empty

View cart

quick search

Vol. 20 Issue 1 (January-March)

Meta-analysis of low molecular weight heparin versus placebo in patients undergoing total hip replacement and post-operative morbidity and mortality since their introduction

Meta-analysis of low molecular weight heparin versus placebo in patients undergoing total hip replacement and post-operative morbidity and mortality since their introduction

Hip Int 2010; 20(1): 64 - 74

Article Type: ORIGINAL ARTICLE

Authors

Andrew Tasker, Roger Harbord, Gordon C. Bannister

Abstract

Objectives: 1) To establish the clinical validity for in-patient low molecular weight heparin (LMWH) following total hip replacement (THR) through a meta-analysis of peer reviewed and published randomised placebo controlled trials (RCTs). 2) To establish whether modern peri-operative practices were associated with changes in rates of clinical venous thromboembolic (VTE) and all-cause mortality after THR by review of series of patients receiving in-patient LMWH published between 1985 and 2000.
Datasources: Medline and Embase (from 1980 to 2005), Datastar and Proquest databases were searched and references from bibliographies traced.
Review methods: Studies of adult patients receiving in-patient LMWH following elective primary or revision THR were sought and data abstracted. The first part of our analysis included only randomised placebo controlled trials. For the second part, randomised control trials were included and divided by their year of completion into three groups.
Results: We found no difference between LMWH and placebo in the risk of fatal pulmonary embolism (PE), other deaths, all cause mortality or major bleeding. LMWH reduced non-fatal PE (OR=0.14, 95%CI 0.03 to 0.74, p=0.029) at the expense of haematoma formation (7/147 vs 0/149, p=0.015). 35 studies were included in the second part of our analysis. Point estimates of rates of fatal and non-fatal pulmonary embolism and other deaths suggest a decline over time but fell short of statistical significance.
Conclusion: Clinically relevant VTEs are a rare complication following THR. The lower risk of VTE narrows the risk benefit of potent pharmacological thromboprophylaxis. We do not support their use in patients undergoing THR without additional thromboembolic risk factors.

Article History

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

Authors

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • If you are not a Subscriber you may:
  • Subscribe to this journal

    Unlimited access to all our archives, 24 hour a day, every day of the week.

    Article price: Eur 36.00

    You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.

  • Claim online access

    If you hold a Society membership and you have never accessed the website claim online access to receive your log in credentials

No supplementary material is available for this article.